Comment: The quality of evidence is downgraded by study limitations (unclear allocation concealment and incomplete assessment of outcome data in half of trials), by publication bias (most of the RCTs were sponsored and by the drug producer), and by indirectness (differences between the population of interest and those studied).
A Cochrane review included 46 studies with a total of 19 976 women. Most RCTs evaluated tibolone for treating menopausal vasomotor symptoms. When compared to placebo, tibolone was more effective in relieving vasomotor symptoms (OR 0.33, 95% CI 0.27 to 0.41; 5 RCTs, n = 842), although only the 2.5 mg/day dose of tibolone was significantly better than placebo (OR 0.25, 95% CI 0.12 to 0.52; 2 RCTs, n = 171). Tibolone was associated with increased vaginal bleeding (OR 2.79, 95% CI 2.10 to 3.70; 9 RCTs, n=7 814). Combined hormone replacement therapy (HT) was more effective than tibolone 2.5 mg/day (OR 1.57, 95% CI 1.18 to 2.1; 4 trials, n=646; moderate quoaity evidence) but tibolone was associated with a lower rate of bleeding (OR 0.32, 95% CI 0.24 to 0.41; 16 RCTs; n=6438 women; moderate-quality evidence) . Among women with a history of breast cancer tibolone increased tumour recurrence (OR 1.50; 95% CI 1.21 to 1.85; 2 trials, n=3 165). However, there was no difference between the groups with no history of breast cancer or outcomes of endometrial cancer, cardiovascular events, venous thromboembolic events, or mortality of any cause.
Date of latest search: 2017-11-29